vs
Side-by-side financial comparison of PROTHENA CORP PUBLIC LTD CO (PRTA) and Vir Biotechnology, Inc. (VIR). Click either name above to swap in a different company.
Vir Biotechnology, Inc. is the larger business by last-quarter revenue ($240.0K vs $21.0K, roughly 11.4× PROTHENA CORP PUBLIC LTD CO). On growth, Vir Biotechnology, Inc. posted the faster year-over-year revenue change (-89.9% vs -99.0%). Over the past eight quarters, PROTHENA CORP PUBLIC LTD CO's revenue compounded faster (-35.2% CAGR vs -88.0%).
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
PRTA vs VIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $240.0K |
| Net Profit | — | $-163.1M |
| Gross Margin | — | — |
| Operating Margin | — | -72267.9% |
| Net Margin | — | -67975.4% |
| Revenue YoY | -99.0% | -89.9% |
| Net Profit YoY | 62.7% | 23.7% |
| EPS (diluted) | — | $-1.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0K | — | ||
| Q3 25 | $2.4M | $240.0K | ||
| Q2 25 | $4.4M | $1.2M | ||
| Q1 25 | $2.8M | $3.0M | ||
| Q4 24 | $2.1M | $12.4M | ||
| Q3 24 | $970.0K | $2.4M | ||
| Q2 24 | $132.0M | $3.1M | ||
| Q1 24 | $50.0K | $56.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-36.5M | $-163.1M | ||
| Q2 25 | $-125.8M | $-111.0M | ||
| Q1 25 | $-60.2M | $-121.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-59.0M | $-213.7M | ||
| Q2 24 | $66.9M | $-138.4M | ||
| Q1 24 | $-72.2M | $-65.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 97.9% | ||
| Q2 24 | — | 98.3% | ||
| Q1 24 | — | 99.9% |
| Q4 25 | — | — | ||
| Q3 25 | -1666.3% | -72267.9% | ||
| Q2 25 | -1914.4% | -9754.3% | ||
| Q1 25 | -2319.0% | -4602.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6857.0% | -9718.7% | ||
| Q2 24 | 44.2% | -5158.7% | ||
| Q1 24 | -163056.0% | -142.0% |
| Q4 25 | — | — | ||
| Q3 25 | -1513.1% | -67975.4% | ||
| Q2 25 | -2845.4% | -9139.9% | ||
| Q1 25 | -2128.5% | -3989.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6082.6% | -8979.7% | ||
| Q2 24 | 50.7% | -4500.1% | ||
| Q1 24 | -144478.0% | -115.8% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.68 | $-1.17 | ||
| Q2 25 | $-2.34 | $-0.80 | ||
| Q1 25 | $-1.12 | $-0.88 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.10 | $-1.56 | ||
| Q2 24 | $1.22 | $-1.02 | ||
| Q1 24 | $-1.34 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.5M | $497.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $280.5M | $796.1M |
| Total Assets | $326.8M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $307.5M | — | ||
| Q3 25 | $330.8M | $497.8M | ||
| Q2 25 | $371.4M | $598.7M | ||
| Q1 25 | $417.9M | $790.9M | ||
| Q4 24 | $471.4M | $901.0M | ||
| Q3 24 | $519.3M | $909.0M | ||
| Q2 24 | $564.1M | $1.1B | ||
| Q1 24 | $546.5M | $1.1B |
| Q4 25 | $280.5M | — | ||
| Q3 25 | $295.0M | $796.1M | ||
| Q2 25 | $324.3M | $947.5M | ||
| Q1 25 | $437.7M | $1.0B | ||
| Q4 24 | $486.9M | $1.2B | ||
| Q3 24 | $534.4M | $1.2B | ||
| Q2 24 | $581.9M | $1.4B | ||
| Q1 24 | $502.4M | $1.5B |
| Q4 25 | $326.8M | — | ||
| Q3 25 | $352.6M | $1.0B | ||
| Q2 25 | $399.1M | $1.2B | ||
| Q1 25 | $495.3M | $1.3B | ||
| Q4 24 | $547.1M | $1.4B | ||
| Q3 24 | $595.3M | $1.5B | ||
| Q2 24 | $645.6M | $1.7B | ||
| Q1 24 | $623.2M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-163.6M | $-167.6M |
| Free Cash FlowOCF − Capex | — | $-167.9M |
| FCF MarginFCF / Revenue | — | -69952.9% |
| Capex IntensityCapex / Revenue | — | 132.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-824.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-163.6M | — | ||
| Q3 25 | $-40.6M | $-167.6M | ||
| Q2 25 | $-46.3M | $-120.2M | ||
| Q1 25 | $-53.4M | $-78.1M | ||
| Q4 24 | $-150.1M | $-446.4M | ||
| Q3 24 | $-45.2M | $-171.5M | ||
| Q2 24 | $16.0M | $-77.8M | ||
| Q1 24 | $-73.1M | $-109.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-167.9M | ||
| Q2 25 | — | $-122.8M | ||
| Q1 25 | — | $-79.7M | ||
| Q4 24 | — | $-453.7M | ||
| Q3 24 | — | $-174.2M | ||
| Q2 24 | — | $-78.5M | ||
| Q1 24 | — | $-111.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | -69952.9% | ||
| Q2 25 | — | -10111.8% | ||
| Q1 25 | — | -2630.1% | ||
| Q4 24 | — | -3666.2% | ||
| Q3 24 | — | -7321.3% | ||
| Q2 24 | — | -2553.3% | ||
| Q1 24 | — | -197.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 132.1% | ||
| Q2 25 | — | 209.1% | ||
| Q1 25 | — | 53.7% | ||
| Q4 24 | — | 59.0% | ||
| Q3 24 | — | 116.3% | ||
| Q2 24 | — | 21.7% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
